title: [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
abstract: Chronic myeloid leukemia (CML) is a hemopoietic condition caused by chromosomal translocation t(9;22)(q34;q11) or bcr-abl fusion gene. The predominant variants of bcr-abl oncogene rearrangement are b3a2 and b2a2. The present study evaluated the efficacy of interferon-a therapy of CML patients and molecular prognostic factors. Cytogenetic response and complete hematological remission were more frequent in CML b3a2 treatment with interferon-a. Moreover, after therapy, chronic phase lasted in that group (p = 0.026) much longer. Overall survival in the group was significantly longer, too (p = 0.046).
authors.affiliation: I.P. Pavlov State Medical University, St. Petersburg.
authors.forename: K V
authors.initials: KV
authors.lastname: Bogdanov
authors.forename: O I
authors.initials: OI
authors.lastname: Frolova
authors.forename: O V
authors.initials: OV
authors.lastname: Marinets
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Ogorodnikova
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Zaritskiĭ
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016898:Interferon-alpha